Can I read Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted on EtoBox?

Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted by Maurizio Benucci; Arianna Damiani; Maria Infantino; Mariangela Manfredi; Barbara Lari; Valentina Grossi; Francesca Li Gobbi; Piercarlo Sarzi-Puttini is a Medicine article available to read on EtoBox.

What is Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted about?

Rheumatoid arthritis (RA) is a chronic inflammatory disease whose natural history leads to articular and extra-articular damage. Both cardiovascular risk and malignancy risk results higher in RA patients, compared to general population. Janus kinase inhibitors (JAKis) are oral targeted synthetic disease modifying antirheumatic drugs (tsDMARDs) that disrupt cytokine cascade and exert anti-inflammatory effects by interfering with signaling through the JAK-STAT intracellular pathways. A recent RCT comparing tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and anti-TNF in rheumatoid arthritis demonstrated an increased risk of MACE HR 1.33 and cancer HR 1.49 at a follow-up of 4 years. This has led the FDA to class warnings for tofacitinib, baricitinib and upadacitinib. Cumulative RCT data, RCT extension data demonstrated a safety profile for Jak inhibitors. Conflicting data results from real life registries; the different selectivity for JAKs (JAK1, JAK2, JAK3 and Tyk2) probably determines differences in efficacy and safety profiles among the members of this group which should actually be evaluated. In order to better understand the cardiovascular and neoplastic risk linked t

Who reads Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted?

Author

Maurizio Benucci; Arianna Damiani; Maria Infantino; Mariangela Manfredi; Barbara Lari; Valentina Grossi; Francesca Li Gobbi; Piercarlo Sarzi-Puttini

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Medicine (Life Sciences)